Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics Revenue

In the fiscal year ending June 30, 2026, Prescient Therapeutics had annual revenue of 3.59M AUD, down -17.60%. Prescient Therapeutics had revenue of 1.16M in the half year ending December 31, 2025, a decrease of -40.31%.

• Revenue: 3.59M
• Revenue Growth: -21.66%
• P/S Ratio: 22.26
• Revenue / Employee: 1.20M
• Employees: 3
• Market Cap: 79.92M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	3.59M	-766.80K	-17.60%
Jun 30, 2025	4.36M	644.03K	17.35%
Jun 30, 2024	3.71M	1.28M	52.89%
Jun 30, 2023	2.43M	538.79K	28.52%
Jun 30, 2022	1.89M	703.86K	59.37%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 21, 2026

Data Sources Report a data error